Fulgent Genetics Stock News

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has received CE certification under the European Union (EU)'s In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) for its germline next-generation sequenc...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, 2025. Management will host a conference call for t...

NEWTOWN, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT), resulting from allegations of providing potentially misleading business information to the investing public.

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) on behalf of Fulgent stockholders. Our investigation concerns whether Fulgent has violated the federal securities laws and/or engaged in other unlawful business pr...

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION  NEW YORK , May 19, 2025 /PRNewswire/ --  Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces   its investigation of potential breaches of fiduciary duty by the Board of Directors and senior management  of Fulgent Genetics, Inc. (NASDAQ: FLGT). Key Details: Subje...

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $73.5 million Core Revenue1 grew 16% year-over-yea...